Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the video below, Tony Wood (SVP Medicinal Science and Technology, GSK R&D) discusses the importance of identification of genetically validated targets, recent investments and why this call is being launched as part of GSK’s strategy.

 Interview transcript

 

  • Applicants should read the call document for further information about the call
  • Please complete the short non-confidential Expression of Interest Form and submit to Charlotte Bell, Business Partnerships Manager, by Friday 28 August 2020.
  • We are encouraging applications to come in throughout July and August so that interested academics can have conversations with GSK discuss potential proposals and seek feedback.
  • Note that proposals do not need to be fully defined at the Expression of Interest stage – ideas that are of interest can be further developed during the second stage of the call. All applications will be reviewed and shortlisted by a GSK expert panel.
  • Prior to submitting your Expression of Interest form, please discuss any issues related to potential IP/freedom to operate restrictions with Charlotte Bell.
  • Shortlisted applicants will be informed by Friday 14 September 2020 at the latest and will be partnered with a GSK scientist to further develop the proposal for presentation to the Joint Steering Committee in late September (Date TBC).
  • Please refer to the Frequently Asked Questions (FAQ) document